Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Posttransplant maintenance therapy in multiple myeloma: the changing landscape.

Sengsayadeth S, Malard F, Savani BN, Garderet L, Mohty M.

Blood Cancer J. 2017 Mar 24;7(3):e545. doi: 10.1038/bcj.2017.23. Review.

2.

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.

Lisenko K, Sauer S, Bruckner T, Egerer G, Goldschmidt H, Hillengass J, Schmier JW, Shah S, Witzens-Harig M, Ho AD, Wuchter P.

BMC Cancer. 2017 Feb 22;17(1):151. doi: 10.1186/s12885-017-3137-4.

3.

New monoclonal antibodies on the horizon in multiple myeloma.

O'Donnell EK, Raje NS.

Ther Adv Hematol. 2017 Feb;8(2):41-53. doi: 10.1177/2040620716682490. Epub 2016 Dec 26. Review.

4.

Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India.

Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, Varma S.

Indian J Hematol Blood Transfus. 2017 Mar;33(1):31-40. doi: 10.1007/s12288-017-0776-1. Epub 2017 Jan 11.

PMID:
28194053
5.

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.

Nadiminti K, Singh Abbi KK, Mott SL, Dozeman L, Tricot A, Schultz A, Behrends S, Zhan F, Tricot G.

Onco Targets Ther. 2017 Jan 6;10:217-226. doi: 10.2147/OTT.S112423. eCollection 2017.

6.

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.

Kwon J, Min CK, Kim K, Han JJ, Moon JH, Kang HJ, Eom HS, Kim MK, Kim HJ, Yoon DH, Lee JO, Lee WS, Lee JH, Lee JJ, Choi YS, Kim SH, Yoon SS.

Cancer Med. 2017 Jan;6(1):100-108. doi: 10.1002/cam4.970. Epub 2016 Dec 1.

7.

The Danish National Multiple Myeloma Registry.

Gimsing P, Holmström MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, Plesner T, Pedersen PT, Frederiksen M, Frølund U, Helleberg C, Vangsted A, de Nully Brown P, Abildgaard N.

Clin Epidemiol. 2016 Oct 25;8:583-587. eCollection 2016. Review.

8.

Recent advances in understanding multiple myeloma.

Dhakal B, Girnius S, Hari P.

F1000Res. 2016 Aug 23;5. pii: F1000 Faculty Rev-2053. doi: 10.12688/f1000research.8777.1. eCollection 2016. Review.

9.

The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.

de Mel S, Chen Y, Gopalakrishnan SK, Ooi M, Teo C, Tan D, Teo ML, Tso AC, Lee LK, Nagarajan C, Goh YT, Chng WJ.

Singapore Med J. 2017 Feb;58(2):55-71. doi: 10.11622/smedj.2016150. Epub 2016 Sep 9.

10.

Recent advances in multiple myeloma: a Korean perspective.

Hong J, Lee JH.

Korean J Intern Med. 2016 Sep;31(5):820-34. doi: 10.3904/kjim.2015.408. Epub 2016 Sep 1. Review.

11.

Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.

Lee HS, Min CK.

Korean J Intern Med. 2016 Sep;31(5):809-19. doi: 10.3904/kjim.2016.110. Epub 2016 Sep 1. Review.

12.

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.

Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS.

Blood Cancer J. 2016 Sep 2;6(9):e466. doi: 10.1038/bcj.2016.68.

13.

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.

Jung SH, Cho MS, Kim HK, Kim SJ, Kim K, Cheong JW, Kim SJ, Kim JS, Ahn JS, Kim YK, Yang DH, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP)..

BMC Cancer. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y.

14.

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.

Magen H, Muchtar E.

Ther Adv Hematol. 2016 Aug;7(4):187-95. doi: 10.1177/2040620716652862. Epub 2016 Jun 10. Review.

15.

The Diagnosis and Treatment of Multiple Myeloma.

Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S.

Dtsch Arztebl Int. 2016 Jul 11;113(27-28):470-6. doi: 10.3238/arztebl.2016.0470.

16.

New investigational drugs with single-agent activity in multiple myeloma.

Rajan AM, Kumar S.

Blood Cancer J. 2016 Jul 29;6(7):e451. doi: 10.1038/bcj.2016.53. Review.

17.

Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Hogan JJ, Weiss BM.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1681-91. doi: 10.2215/CJN.03160316. Epub 2016 Jul 14. Review.

PMID:
27416775
18.

Advances in the Use of Stem Cells in Veterinary Medicine: From Basic Research to Clinical Practice.

Markoski MM.

Scientifica (Cairo). 2016;2016:4516920. doi: 10.1155/2016/4516920. Epub 2016 Jun 9. Review.

19.

First line vs delayed transplantation in myeloma: Certainties and controversies.

Brioli A.

World J Transplant. 2016 Jun 24;6(2):321-30. doi: 10.5500/wjt.v6.i2.321. Review.

20.

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.

D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P.

Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14170. [Epub ahead of print] No abstract available.

PMID:
27292583

Supplemental Content

Support Center